We are live on ! Find out more
HALO icon

Halozyme

161 hedge funds and large institutions have $909M invested in Halozyme in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 50 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

359% more call options, than puts

Call options by funds: $14M | Put options by funds: $3.04M

18% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 50

0% more funds holding

Funds holding: 161161 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

6% less capital invested

Capital invested by funds: $967M → $909M (-$57.7M)

Holders
161
Holders Change
Holders Change %
0%
% of All Funds
4.3%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
59
Reduced
50
Closed
18
Calls
$14M
Puts
$3.04M
Net Calls
+$10.9M
Net Calls Change
-$5.71M
Name Holding Trade Value Shares
Change
Change in
Stake
Envestnet Asset Management
176
Envestnet Asset Management
Illinois
-$16K -1,643 Closed
TFA
177
Transamerica Financial Advisors
Florida
-$11K -1,100 Closed
WTB
178
Washington Trust Bank
Washington
-$5K -500 Closed
SCA
179
Stuart Chaussee & Associates
California
-$3K -260 Closed

HALO Hedge Fund Activity: Q2 2016 in Review

161 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2016, worth a combined $909M — down 6% from $967M a quarter earlier.

Fund positioning in HALO was balanced in Q2 2016: 18 funds opened new positions, 18 closed out, 59 added to existing stakes and 50 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $17.6M. The largest seller was Invesco, cutting an estimated $9.18M.

  • 161 institutional investors held Halozyme (HALO) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $909M of Halozyme stock for Q2 2016, down 6% quarter-over-quarter.
  • 18 funds opened new Halozyme positions in Q2 2016 and 18 closed out, a net change of 0 holders.
  • The largest Halozyme buyer in Q2 2016 was Bank of New York Mellon, an estimated $17.6M added.
  • The largest Halozyme seller in Q2 2016 was Invesco, an estimated $9.18M sold.

Based on aggregated 13F filings for Q2 2016.